• Mashup Score: 0

    In a Healio video exclusive, Jan Wehkamp, MD, PhD, reports that treatment with Tremfya maintained clinical remission and endoscopic response through 3 years among patients with moderate to severe Crohn’s disease. “There is still tremendous unmet need for patients with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis,” Wehkamp, vice president and

    Tweet Tweets with this article
    • In a @GoHealio #GI 🎥 exclusive from #UEGWeek23: Jan Wehkamp, MD, PhD 👨🏻‍⚕️, of @JanssenUS, reports that treatment with #Tremfya maintained clinical remission and endoscopic response through 3 years among patients with #Crohnsdisease. Learn more 👇🏼 https://t.co/E2umREDIhy

  • Mashup Score: 0

    Submit yourself, or a peer, for an open AGA leadership role through the fall.

    Tweet Tweets with this article
    • Interested in building education programs focused on the most pressing issues in #GI? Nominate yourself or a peer for the #AGA Institute Council, AGA’s committees or to serve as one of AGA’s course directors. Nominations are being accepted through Nov. 1. https://t.co/ERrl15em8N https://t.co/lWMs8vNPT6

  • Mashup Score: 3

    Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often both its cause and its cure.The broad-spectrum antibiotics doled out to treat infections also radically alter the composition of the microbiota, wiping out a significant portion of the bacterial community and upsetting the natural balance of gut flora. Without competition from healthy

    Tweet Tweets with this article
    • In @GoHealio #GI’s latest cover story 📰, experts across the field discussed the shift in #Cdiff treatment and potential risks new therapies that have yet to been explored. Read the full story at the 🔗below👇🏻 #GITwitter #MedTwitter https://t.co/VA9H0FVy7e